Open AccessResveratrol ameliorates Lewis lung carcinoma‐bearing mice development, decreases granulocytic myeloid‐derived suppressor cell accumulation and impairs its suppressive ability
Author(s) -
Zhao Yilin,
Shao Qi,
Zhu Haitao,
Xu Haiyuan,
Long Wei,
Yu Bin,
Zhou Lining,
Xu Huaxi,
Wu Yan,
Su Zhaoliang
Publication year - 2018
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.13720
Subject(s) - myeloid derived suppressor cell , lewis lung carcinoma , resveratrol , cancer research , immunology , population , myeloid , chemistry , immunotherapy , suppressor , medicine , pharmacology , immune system , cancer , metastasis , environmental health
Myeloid‐derived suppressor cells ( MDSC ) are a heterogeneous population of immature myeloid cells which consist of 2 subsets: granulocytic MDSC (G‐ MDSC ) and monocytic MDSC (M‐ MDSC ). MDSC expand in tumor‐bearing hosts and contribute to immunotherapeutic resistance by remarkably blocking effector T‐cell activation via different mechanisms. Resveratrol ( RSV ) is a polyphenol and it has been widely used for its various health benefits. However, the underlying mechanism of its anti‐tumor properties remains unclear. In this study, a transplantable mouse model was used to investigate the effects of RSV on MDSC . The results showed that RSV ameliorated tumor development by decreasing G‐ MDSC accumulation, impairing its suppressive ability on CD 8 + T cells and promoting M‐ MDSC differentiation into CD 11c + and F4/80 + cells. Our results indicated that RSV should be considered as a modular of MDSC suppressive function and that RSV is a novel booster for tumor immunotherapy.